Ningxia Zhongke Biotechnology Co (SHSE:600165) EBITDA: ¥-122.1 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600165 Ningxia Zhongke Biotechnology Co Ltd SHSE:600165
53 GF Score
Price ¥2.43
GF Value ¥2.77
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Ningxia Zhongke Biotechnology Co EBITDA?

Ningxia Zhongke Biotechnology Co SHSE:600165 +9.95% 53 EBITDA is ¥-122.1 Mil as of Mar. 2026. GuruFocus rates SHSE:600165 with a GF Score™ of 53/100 and a GF Value™ of ¥2.77 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Ningxia Zhongke Biotechnology Co's EBITDA for the three months ended in Mar. 2026 was ¥-61.4 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ¥-122.1 Mil.

During the past 3 years, the average EBITDA Growth Rate was 54.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of Ningxia Zhongke Biotechnology Co was 54.10% per year. The lowest was -72.10% per year. And the median was 11.20% per year.

Ningxia Zhongke Biotechnology Co's EBITDA per Share for the three months ended in Mar. 2026 was ¥-0.04. Its EBITDA per share for the trailing twelve months (TTM) ended in Mar. 2026 was ¥-0.23.

During the past 3 years, the average EBITDA per Share Growth Rate was 63.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of Ningxia Zhongke Biotechnology Co was 63.50% per year. The lowest was -72.40% per year. And the median was 10.90% per year.

Ningxia Zhongke Biotechnology Co  (SHSE:600165) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


Ningxia Zhongke Biotechnology Co EBITDA Related Terms


Ningxia Zhongke Biotechnology Co EBITDA Historical Data

* Premium members only.

The historical data trend for Ningxia Zhongke Biotechnology Co's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ningxia Zhongke Biotechnology Co EBITDA Chart

Ningxia Zhongke Biotechnology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -96.65 -28.26 -235.17 -306.27 -2.73

Ningxia Zhongke Biotechnology Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -69.85 -106.95 -82.15 128.44 -61.43

SHSE:600165 vs LIN, SHW, ECL: EBITDA Comparison

For the Specialty Chemicals subindustry, Ningxia Zhongke Biotechnology Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ningxia Zhongke Biotechnology Co EV-to-EBITDA vs Chemicals Industry

For the Chemicals industry and Basic Materials sector, Ningxia Zhongke Biotechnology Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Ningxia Zhongke Biotechnology Co's EV-to-EBITDA falls into.


SHSE:600165
53GF Score
Ningxia Zhongke Biotechnology Co Ltd SHSE:600165
EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Ningxia Zhongke Biotechnology Co's EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Ningxia Zhongke Biotechnology Co's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Dec. 2025, Ningxia Zhongke Biotechnology Co's EBITDA was ¥-2.7 Mil.

Ningxia Zhongke Biotechnology Co's EBITDA for the quarter that ended in Mar. 2026 is calculated as

Ningxia Zhongke Biotechnology Co's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Mar. 2026, Ningxia Zhongke Biotechnology Co's EBITDA was ¥-61.4 Mil.

EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-122.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Frequently Asked Questions Learn more about EBITDA →
What does a EBITDA of ¥-122.1 Mil mean?
Ningxia Zhongke Biotechnology Co (SHSE:600165) has a EBITDA of ¥-122.1 Mil as of Mar. 2026. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on Ningxia Zhongke Biotechnology Co.
Is Ningxia Zhongke Biotechnology Co's EBITDA too high?
Ningxia Zhongke Biotechnology Co's current EBITDA is ¥-122.1 Mil. Overall, Ningxia Zhongke Biotechnology Co has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ningxia Zhongke Biotechnology Co's EBITDA compare to LIN and SHW?
Ningxia Zhongke Biotechnology Co's EBITDA of ¥-122.1 Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA for a Chemicals company?
A good EBITDA depends on the Chemicals industry context. However, EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA mean?
A high EBITDA can signal that a stock is expensive relative to its fundamentals. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on Ningxia Zhongke Biotechnology Co. Ningxia Zhongke Biotechnology Co's current EBITDA is ¥-122.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ningxia Zhongke Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Ningxia Zhongke Biotechnology Co (SHSE:600165) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥2.77, compared to a current price of ¥2.43 — trading 12.3% below its estimated fair value. The current EBITDA is ¥-122.1 Mil. Ningxia Zhongke Biotechnology Co's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA calculated?
EBITDA is calculated from a company's financial statements. For Ningxia Zhongke Biotechnology Co (SHSE:600165), the current EBITDA is ¥-122.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ningxia Zhongke Biotechnology Co (SHSE:600165) Overvalued in 2026?

Based on GuruFocus' analysis, Ningxia Zhongke Biotechnology Co stock appears to be undervalued. The current stock price of ¥2.43 is trading 12.3% below its estimated GF Value™ of ¥2.77. GuruFocus considers Ningxia Zhongke Biotechnology Co to be Modestly Undervalued.

Key valuation signals for SHSE:600165:

  • EBITDA: ¥-122.1 Mil
  • GF Value™: ¥2.77 vs. price of ¥2.43 (12.3% below fair value)
  • GF Score™: 53/100 with 4 warning signs

No single metric tells the full story. See the SHSE:600165 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ningxia Zhongke Biotechnology Co Business Description

Address Hebin Street, Ningxia Hui Autonomous Region, Huinong District, Shizuishan, CHN, 750002
Ningxia Zhongke Biotechnology Co Ltd is engaged in the production and sales of activated carbon products, preparation and storage of stem cells, trade and other businesses, as well as lauric acid.
53GF Score

Get the complete analysis for SHSE:600165

EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥2.43
Price
¥2.77
GF Value